Skip to content

KDK KDK Change in fair value of second lien loans

Change in fair value of second lien loans at other companies

Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$1.47M-3.9%
GeneDx Holdings logo
GeneDx HoldingsWGS
$2.54M+331%
Evommune
 logo
Evommune EVMN
$206.46K-88.8%
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
-$4.26M-37.8%
Limbach Holdings, Inc. logo
Limbach Holdings, Inc.LMB
$38K+139%
FS KKR Capital Corp. logo
FS KKR Capital Corp.FSK
$9M+190%

Other financials

Income statement

See full
Revenue$1.8M+24.4%
Operating income-$37.9M-104%
Net income$26.5M+121%
EPS (diluted)$0.10+105%

Balance sheet

See full
Cash & equivalents$66.4M+247%
Total debt$58.4M+1,068%
Total equity-$245.9M+34.7%
Total assets$130.8M-76.5%

Cash flow

See full
Operating cash flow-$29.5M-78.7%
CapEx$5.5M+138%
Free cash flow-$35.0M-86.0%

Valuation

See full
Market cap$1.05B-18.6%
Enterprise value$1.04B
P/S252.8×

Profitability

See full
Operating margin-2,695.8%
Net margin-10,366.9%
FCF margin-278%

Returns & leverage

See full
Return on equity-21.5%
Debt / equity-0.2×
Current ratio3.7×+3.4×

Where this comes from

Reported directly by KDK in its filing.

Tagged under the XBRL concept kdk:FairValueAdjustmentOfConvertibleDebt.

The official record: KDK’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about KDK's change in fair value of second lien loans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KDK's change in fair value of second lien loans?
KDK (KDK) reported change in fair value of second lien loans of $474K in Q1 2026.
What does change in fair value of second lien loans mean?
This metric tracks the periodic fluctuations in the fair value of second lien debt instruments that contain embedded derivatives or conversion features. It captures market-driven volatility in the company's debt obligations and the impact of changing credit conditions on financial liabilities.